Thursday, 19 January 2023, 09:35 HKT/SGT

Source: Eisai

TOKYO, Jan 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel). Eisai Israel is a wholly-owned subsidiary of Eisai's European regional headquarters, Eisai Europe Ltd.

Israel's pharmaceutical market reached 5.3 billion USD in 2021.1 The compound annual growth rate of the Israel pharmaceutical market from 2018 to 2021 was +8.56%1 and the market is expected to continue to grow steadily, with a high penetration rate of innovative medicines.

In 2011, Eisai Europe started business in Israel marketing and selling Eisai products through local distribution partners, and mainly marketed Lenvima, Halaven, Fycompa and Inovelon. Eisai Israel was established in August 2021, and in January 2023, became the marketing authorization holder of the Eisai products in Israel. Eisai Israel will now perform sales and marketing activities for these products. The company plans to launch its other global brands in the future.

With the commencement of operations at Eisai Israel, Eisai aims to utilize its own drug sales system in Israel, deliver innovative new drugs to more patients in Israel as quickly as possible, and contribute to improving the benefits of patients and their families.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network

Eisai

Dec 11, 2025 18:41 HKT/SGT

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

Dec 9, 2025 17:51 HKT/SGT

"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Dec 4, 2025 17:36 HKT/SGT

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025

Dec 3, 2025 17:19 HKT/SGT

New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Dec 2, 2025 23:01 HKT/SGT

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025

Nov 28, 2025 22:00 HKT/SGT

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan

Nov 26, 2025 18:42 HKT/SGT

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Nov 17, 2025 21:08 HKT/SGT

"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Oct 30, 2025 13:43 HKT/SGT

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

Oct 28, 2025 23:30 HKT/SGT

Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

More news >>

News Alerts


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Privacy Policy \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575

Connect With us: